Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Colonic Neoplasms 1Carcinoma 1Adenocarcinoma 1

Interventions

pembrolizumab 17Cisplatin 11Carboplatin 9Cyclophosphamide 8fludarabine 6Paclitaxel 6Nivolumab 6Bevacizumab 6aldesleukin 5Radiotherapy 5toripalimab 4tisotumab vedotin 4fludarabine phosphate 4Topotecan 4Interleukin-2 4Docetaxel 4Brachytherapy 4spartalizumab 3Ipilimumab 3Fulvestrant 3ferumoxtran-10 2enzalutamide 2durvalumab 2cemiplimab 2bemarituzumab 2balstilimab 2Trastuzumab 2Radiation 2Magnetic Resonance Spectroscopy 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Uterine Cervical Neoplasms × balstilimab × Clear all
NCT03104699 2025-07-30

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Agenus Inc.

Phase 1/2 Completed
211 enrolled 29 charts
Gynecologic

Uterine Cervical Neoplasms

NCT03495882 2023-07-05

Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Agenus Inc.

Phase 1/2 Completed
154 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡